Immunohistochemical Analysis of CYP11B2, CYP11B1 and β-catenin Helps Subtyping and Relates With Clinical Characteristics of Unilateral Primary Aldosteronism

被引:4
|
作者
Sun, Luyan [1 ]
Jiang, Yiran [1 ]
Xie, Jing [2 ]
Zhu, Hongyuan [1 ]
Wu, Luming [1 ]
Zhong, Xu [1 ]
Zhou, Weiwei [1 ]
Su, Tingwei [1 ]
Wang, Weiqing [1 ,3 ,4 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Key Lab Endocrine Tumors, Shanghai Clin Ctr Endocrine & Metab Dis,Sch Med, Shanghai Inst Endocrine & Metab Dis,Ruijin Hosp, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Pathol, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Lab Endocrine & Metab Dis, Sch Med, Inst Hlth Sci, Shanghai, Peoples R China
[4] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai, Peoples R China
基金
中国国家自然科学基金; 欧洲研究理事会;
关键词
hyperaldosteronism; beta catenin; immunohistochemistry; prognosis; ADRENALECTOMY; EXPRESSION; HYPERALDOSTERONISM; HYPERTENSION; HYPERPLASIA; MUTATIONS; DIAGNOSIS; ADENOMAS; OUTCOMES; SUBUNIT;
D O I
10.3389/fmolb.2021.751770
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Primary aldosteronism is caused by aldosterone overproduction. While conventional hematoxylin-eosin staining can demonstrate morphological abnormality, it cannot provide any functional histopathological information. We aimed to identify the diagnostic, functional and prognostic value of CYP11B2, CYP11B1, and beta-catenin immunostaining in unilateral hyperaldosteronism. Method: A total of 134 patients with unilateral hyperaldosteronism were recruited in our study. The expression of CYP11B2, CYP11B1, and beta-catenin was evaluated semiquantitatively on 134 patients' sections using immunohistochemistry technology and the relationship with clinical data was assessed. Results: Patients were classified into four subtypes based on CYP11B2 staining as below: (1)118 patients with unilateral single aldosterone-producing adenoma (APA), (2)11 with unilateral multiple APA, (3)four with aldosterone-producing cell cluster (APCC), and (4)one with an undefined source. Adjusted CYP11B2 H-score was correlated with serum aldosterone, aldosterone to renin ratio (ARR), and serum potassium. In the abnormal beta-catenin staining group, hypertension duration, aldosterone, ARR, cortisol, tumor diameter, tumor area, and CYP11B2 H-score were significantly higher than those of the wild-type group. Serum potassium level was significantly lower in the abnormal beta-catenin staining group. Age, gender, BMI, family history of hypertension, adjusted CYP11B2 and CYP11B1 H-scores differed significantly between complete clinical success and incomplete clinical success groups. Age, gender and family history of hypertension were independently associated with complete clinical success based on multivariate logistic regression analysis. Conclusion: CYP11B2 immunostaining could improve the differential diagnosis of unilateral hyperaldosteronism. Adjusted CYP11B2 H-score could be used as a histopathological marker to reflect the severity of unilateral APA. Dysregulation of Wnt/beta-catenin signaling and impaired beta-catenin degradation may provoke the proliferation and enhance the steroidogenic ability of APA tumor cells, indicating that the Wnt pathway might be a potential, actionable, therapeutic target in the treatment of hyperaldosteronism. Age, sex and family history of hypertension were independent predictors of clinical outcome after adrenalectomy for unilateral hyperaldosteronism.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Control of CYP11B2/CYP11B1 Expression Ratio and Consequences for the Zonation of the Adrenal Cortex
    Dringenberg, T.
    Schwitalla, M.
    Haase, M.
    Scherbaum, W. A.
    Willenberg, H. S.
    HORMONE AND METABOLIC RESEARCH, 2013, 45 (02) : 81 - 85
  • [22] Quantitative assessment of CYP11B1 and CYP11B2 expression in aldosterone-producing adenomas
    Fallo, F
    Pezzi, V
    Barzon, L
    Mulatero, P
    Veglio, F
    Sonino, N
    Mathis, JM
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2002, 147 (06) : 795 - 802
  • [23] Adrenal CYP11B1/2 expression in primary aldosteronism: Immunohistochemical analysis using novel monoclonal antibodies
    Nakamura, Yasuhiro
    Maekawa, Takashi
    Felizola, Saulo J. A.
    Satoh, Fumitoshi
    Qi, Xin
    Velarde-Miranda, Carolina
    Plonczynski, Maria W.
    Ise, Kazue
    Kikuchi, Kumi
    Rainey, William E.
    Gomez-Sanchez, Elise P.
    Gomez-Sanchez, Celso E.
    Sasano, Hironobu
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2014, 392 (1-2) : 73 - 79
  • [24] Common Polymorphisms in the CYP11B1 and CYP11B2 Genes: Evidence for a Digenic Influence on Hypertension
    Alvarez-Madrazo, Samantha
    MacKenzie, Scott M.
    Davies, Eleanor
    Fraser, Robert
    Lee, Wai-Kwong
    Brown, Morris
    Caulfield, Mark J.
    Dominiczak, Anna F.
    Farrall, Martin
    Lathrop, Mark
    Hedner, Thomas
    Melander, Olle
    Munroe, Patricia B.
    Samani, Nilesh
    Stewart, Paul M.
    Wahlstrand, Bjorn
    Webster, John
    Palmer, Colin N. A.
    Padmanabhan, Sandosh
    Connell, John M.
    HYPERTENSION, 2013, 61 (01) : 232 - +
  • [25] Double CYP11B1/CYP11B2 Immunohistochemistry and Detection of KCNJ5 Mutations in Primary Aldosteronism (Jun, dgae411, 2024)
    Caroccia, B.
    Lenzini, L.
    Ceolotto, G.
    Gioco, F.
    Benetti, A.
    Giannella, A.
    Ajjour, H.
    Galuppini, F.
    Pennelli, G.
    Seccia, T. M.
    Gomez-Sanchez, C.
    Rossi, G. P.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (10): : e1983 - e1983
  • [26] Exploring QSAR for CYP11B2 binding affinity and CYP11B2/CYP11B1 selectivity of diverse functional compounds using GFA and G/PLS techniques
    Roy, Partha P.
    Roy, Kunal
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2010, 25 (03) : 354 - 369
  • [27] Regulation of human CYP11B1 and CYP11B2 promoters by transposable elements and conserved cis elements
    Cheng, Li-Chuan
    Pai, Tun-Wen
    Li, Lih-Ann
    STEROIDS, 2012, 77 (1-2) : 100 - 109
  • [28] Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors
    Papillon, Julien P. N.
    Adams, Christopher M.
    Hu, Qi-Ying
    Lou, Changgang
    Singh, Alok K.
    Zhang, Chun
    Carvalho, Jose
    Rajan, Srinivan
    Amaral, Adam
    Beil, Michael E.
    Fu, Fumin
    Gangl, Eric
    Hu, Chii-Whei
    Jeng, Arco Y.
    LaSala, Daniel
    Liang, Guiqing
    Logman, Michael
    Maniara, Wieslawa M.
    Rigel, Dean F.
    Smith, Sherri A.
    Ksander, Gary M.
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (11) : 4749 - 4770
  • [29] Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors
    Meredith, Erik L.
    Ksander, Gary
    Monovich, Lauren G.
    Papillon, Julien P. N.
    Liu, Qian
    Miranda, Karl
    Morris, Patrick
    Rao, Chang
    Burgis, Robin
    Capparelli, Michael
    Hu, Qi-Ying
    Singh, Alok
    Rigel, Dean F.
    Jeng, Arco Y.
    Beil, Michael
    Fu, Fumin
    Hu, Chii-Whei
    LaSala, Daniel
    ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (12): : 1203 - 1207
  • [30] A novel chimeric CYP11B2/CYP11B1 combined with a new p.L340P CYP11B1 mutation in a patient with 11OHD: case report
    Duan, Lian
    Shen, Rufei
    Song, Lingyu
    Liao, Yong
    Zheng, Hongting
    BMC ENDOCRINE DISORDERS, 2018, 18